长链非编码RNAH19在甲状腺癌中的表达及预后预测的研究

Abstract
Figure/Table
References (20)
Related Citation (15)

Download: PDF (711 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the expression of long non-coding RNA H19 (lncRNA H19) in thyroid carcinoma (TC), and its correlation with the clinicopathologic characteristics and prognosis of TC. Methods From January 2009 to January 2012, 131 TC tissues and adjacent tissues were collected from patients after thyroid surgery between as case group. Concurrently, additional 122 normal thyroid tissues from patients with benign thyroid lesions were obtained as normal control group. The expression level of lncRNA H19 were detected by quantitative real-time PCR (qRT-PCR). five years follow-ups were conducted. Receiver operating curve(ROC) was used to evaluate the diagnostic values of lncRNA H19 for TC. The Kaplan-Meier method were employed to analyze 5-year survival rate of TC patient. Both univariate and multivariate analyses were performed to analyze the prognostic factors of TC. Results The lncRNA H19 expression was higher in TC tissues than that in the adjacent and normal tissues(P < 0.05). The area under the ROC curve(AUC) of lncRNA H19 were 0.801. Diagnostic boundary point was 3.58. Sensitivity and specificity was 72.5% and 75.4% respectively. Youden index was 0.479. The lncRNA H19 expression in TC tissue with tumor diameter no less than 1 cm, TNM Ⅲ+Ⅳ stage, or lymph node metastasis was evidently higher than that in TC tissue with tumor smaller than 1 cm, TNM Ⅰ+Ⅱ stage, or without lymph node metastasis(P < 0.05). The 5-year survival rate of TC patients with high lncRNA H19 expression declined (28.44%). The expression of lncRNA H19, tumor diameter, TNM stage and lymph node metastasis were independent prognostic factors of TC patients (P < 0.05). Conclusion The increased lncRNA H19 expression levels are associated with clinicopathologic characteristics and poor prognosis in TC patients. And it may be one of the molecular regulation mechanism in TC occurrence and development. This study also can provide basis for noninvasive diagnosis and therapeutic target searching in TC.

Key words： Thyroid carcinoma Long non-coding RNAs lncRNA H19 Prognosis

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LIU Na1 QI Yanhua1 ZHOU Qi1 CHENG Chuantao2 YANG Wenbin2

Cite this article:

LIU Na1 QI Yanhua1 ZHOU Qi1 CHENG Chuantao2 YANG Wenbin2. Expression status and prognostic significance of lncRNA H19 in thyroid carcinoma[J]. 中国医药导报, 2018, 15(13): 25-30.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2018/V15/I13/25

[1] La VC，Malvezzi M，Bosetti C，et al. Thyroid cancer mortality and incidence： a global overview [J]. INT J Cancer，2015，136（9）：2187-2195.
[2] Deirdre K，Catherine MK. Clinical overview of thyroid cancer and recent advances in treatment [J]. J Oncol Med ＆ Pract，2016，1（2）：1-6.
[3] Chen T，Yang P，He ZY. Long noncoding RNA H19 can predict a poor prognosis and lymph node metastasis：a meta-analysis in human cancer [J]. Minerva Medica，2016， 107（4）：251-258.
[4] Liz J，Esteller M. LncRNAs and microRNAs with a role in cancer development [J]. Biochimica Et Biophysica Acta，2016，1859（1）：169-177.
[5] 赵青芳，关露露，陈小兵.长链非编码RNA在胃癌中作用机制的研究进展[J].中国医药导报，2017，14（8）：33-36.
[6] 张明娇，吴勇，李珉珉.长链非编码RNAs的生物功能及其与器官发育和恶性肿瘤的关系[J].中国病理生理杂志，2015，31（11）：2107-2112.
[7] Kim M，Kim WG，Oh HS，et al. Comparison of the seventh and eighth editions of the American Joint Committee on Cancer/Union for international cancer control Tumor-Node-Metastasis Staging System for differentiated thyroid cancer [J]. Thyroid，2017，27（9）：1149-1155.
[8] 魏晨晨，王朝霞.长链非编码RNA H19在肿瘤研究中的进展[J].临床肿瘤学杂志，2015，20（11）：1041-1044.
[9] Liz J，Esteller M. lncRNAs and microRNAs with a role in cancer development [J]. Biochimica Et Biophysica Acta，2016，1859（1）：169-177.
[10] Zhang T，Wang Y R，Zeng F，et al. LncRNA H19 is overexpressed in glioma tissue，is negatively associated with patient survival，and promotes tumor growth through its derivative miR-675 [J]. Eur Rev Med Pharmacol Sci，2016， 56 20（23）：4891-4897.
[11] 许敏，吕述彦.印记基因与胎儿生长发育关系的研究进展[J].山东医药，2016，（1）：102-104.
[12] Zhang DM，Lin ZY，Yang ZH，et al. LncRNA H19 promotes tongue squamous cell carcinoma progression through β-catenin/GSK3β/EMT signaling via association with EZH2 [J]. Am J Transl Res，2017，9（7）：3474-3486.
[13] Wang SH，Wu XC，Zhang MD，et al. Upregulation of H19 indicates a poor prognosis in gallbladder carcinoma and promotes epithelial-mesenchymal transition [J]. AM J Cancer Res，2016，6（4）：15-26.
[14] Looijenga LH，Verkerk AJ，De GN，et al. H19 in normal development and neoplasia [J]. Mol Reprod Dev，2015， 46（3）：419-439.
[15] Wang H，Men CP. Correlation of Increased Expression of MicroRNA-155 in Bladder Cancer and Prognosis [J]. Lab Med，2015，46（2）：118-122.
[16] Hua Q，Lv X，Gu X，et al. Genetic variants in lncRNA H19 are associated with the risk of bladder cancer in a Chinese population [J]. Mutagenesis，2016，31（5）：531-538.
[17] Chen JS，Wang YF，Zhang XQ，et al. H19 serves as a diagnostic biomarker and up-regulation of H19 expression contributes to poor prognosis in patients with gastric cancer [J]. Neoplasma，2016，63（2）：223-230.
[18] Raveh E，Matouk IJ，Gilon M，et al. The H19 Long non-coding RNA in cancer initiation，progression and metastasis-a proposed unifying theory [J]. Mol Cancer，2015， 14（1）：184-198.
[19] Liu C，Chen Z，Fang J，et al. H19-derived miR-675 contributes to bladder cancer cell proliferation by regulating p53 activation：[J]. Tumor Biol，2016，37（1）：263-270.
[20] Zhang K，Luo Z，Zhang Y，et al. Circulating lncRNA H19 in plasma as a novel biomarker for breast cancer [J]. Cancer Biomark，2016，17（2）：187-194.